心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
Chinese Journal of Cardiovascular Rehabilitation Medicine
2015年
6期
640-643
,共4页
刘英%白晟遥%高辉%李红%刘惠亮
劉英%白晟遙%高輝%李紅%劉惠亮
류영%백성요%고휘%리홍%류혜량
冠心病%高半胱氨酸%C反应蛋白质
冠心病%高半胱氨痠%C反應蛋白質
관심병%고반광안산%C반응단백질
Coronary disease%Homocysteine%C-reactive protein
目的:分析降同型半胱氨酸(Hcy)疗法对冠心病介入治疗后血清Hcy、炎性因子水平的影响。方法:选择在本院接受介入治疗的82例冠心病患者作为研究对象,按照随机数字表法被分为接受术后常规治疗的常规治疗组(41例)和降Hcy组(41例),比较两组患者的血清Hcy、炎症因子、N末端脑钠肽前体(NT‐proBNP)及可溶性细胞间粘附因子‐1(sICAM‐1)水平差异。结果:1)治疗6个月及1年后,与常规治疗组比较,降 Hcy组血清Hcy水平均显著降低[6个月后:(15.39±1.83)μmol/L比(13.21±1.35)μmol/L ,1年后:(15.61±1.62)μmol/L比(8.73±0.72)μmol/L];2)治疗6个月后,与常规治疗组比较,降Hcy组血清CRP [(67.27±7.51) mg/L比(37.11±6.32) mg/L]、IL‐6[(87.58±7.21)μg/L比(60.17±5.45)μg/L]、前降钙素[PCT ,(21.34±3.04) ng/L比(15.61±2.32) ng/L]、NT‐proBNP [(298.37±53.28) pg/ml比(104.28±13.17) pg/ml]及sI‐CAM‐1[(391.83±75.04) ng/ml比(162.18±30.26) ng/ml]水平均明显降低(P均<0.05)。结论:降同型半胱氨酸疗法有助于降低冠心病介入治疗后患者的血清同型半胱氨酸水平,减轻全身炎症反应,保护心肌功能。
目的:分析降同型半胱氨痠(Hcy)療法對冠心病介入治療後血清Hcy、炎性因子水平的影響。方法:選擇在本院接受介入治療的82例冠心病患者作為研究對象,按照隨機數字錶法被分為接受術後常規治療的常規治療組(41例)和降Hcy組(41例),比較兩組患者的血清Hcy、炎癥因子、N末耑腦鈉肽前體(NT‐proBNP)及可溶性細胞間粘附因子‐1(sICAM‐1)水平差異。結果:1)治療6箇月及1年後,與常規治療組比較,降 Hcy組血清Hcy水平均顯著降低[6箇月後:(15.39±1.83)μmol/L比(13.21±1.35)μmol/L ,1年後:(15.61±1.62)μmol/L比(8.73±0.72)μmol/L];2)治療6箇月後,與常規治療組比較,降Hcy組血清CRP [(67.27±7.51) mg/L比(37.11±6.32) mg/L]、IL‐6[(87.58±7.21)μg/L比(60.17±5.45)μg/L]、前降鈣素[PCT ,(21.34±3.04) ng/L比(15.61±2.32) ng/L]、NT‐proBNP [(298.37±53.28) pg/ml比(104.28±13.17) pg/ml]及sI‐CAM‐1[(391.83±75.04) ng/ml比(162.18±30.26) ng/ml]水平均明顯降低(P均<0.05)。結論:降同型半胱氨痠療法有助于降低冠心病介入治療後患者的血清同型半胱氨痠水平,減輕全身炎癥反應,保護心肌功能。
목적:분석강동형반광안산(Hcy)요법대관심병개입치료후혈청Hcy、염성인자수평적영향。방법:선택재본원접수개입치료적82례관심병환자작위연구대상,안조수궤수자표법피분위접수술후상규치료적상규치료조(41례)화강Hcy조(41례),비교량조환자적혈청Hcy、염증인자、N말단뇌납태전체(NT‐proBNP)급가용성세포간점부인자‐1(sICAM‐1)수평차이。결과:1)치료6개월급1년후,여상규치료조비교,강 Hcy조혈청Hcy수평균현저강저[6개월후:(15.39±1.83)μmol/L비(13.21±1.35)μmol/L ,1년후:(15.61±1.62)μmol/L비(8.73±0.72)μmol/L];2)치료6개월후,여상규치료조비교,강Hcy조혈청CRP [(67.27±7.51) mg/L비(37.11±6.32) mg/L]、IL‐6[(87.58±7.21)μg/L비(60.17±5.45)μg/L]、전강개소[PCT ,(21.34±3.04) ng/L비(15.61±2.32) ng/L]、NT‐proBNP [(298.37±53.28) pg/ml비(104.28±13.17) pg/ml]급sI‐CAM‐1[(391.83±75.04) ng/ml비(162.18±30.26) ng/ml]수평균명현강저(P균<0.05)。결론:강동형반광안산요법유조우강저관심병개입치료후환자적혈청동형반광안산수평,감경전신염증반응,보호심기공능。
Objective:To analyze therapeutic effect of homocysteine (Hcy)‐lowering therapy on serum levels of Hcy and inflammatory factors in patients with coronary heart disease (CHD ) after percutaneous coronary intervention (PCI) .Methods :A total of 82 CHD patients who received PCI in our hospital were selected .According to random number table ,they were randomly and equally divided into routine treatment group (received routine postoperative therapy) and Hcy‐lowering group .Serum levels of Hcy ,inflammatory factors ,N‐terminal pro‐brain natriuretic pep‐tide (NT‐proBNP) and soluble intercellular adhesion molecule‐1 (sICAM‐1) were compared between two groups . Results :1) On six months and one year after treatment ,compared with routine treatment group ,serum Hcy level significantly reduced [after six months: (15.39 ± 1.83) μmol/L vs . (13.21 ± 1.35) μmol/L ,after one year :(15.61 ± 1.62)μmol/L vs . (8.73 ± 0.72)μmol/L] in Hcy‐lowering group ;2) after six‐month treatment ,compared with routine treatment group ,there were significant reductions in serum levels of CRP [ (67.27 ± 7.51) mg/L vs . (37.11 ± 6.32) mg/L] ,IL‐6 [ (87.58 ± 7.21)μg/L vs . (60.17 ± 5.45)μg/L] ,procalcitonin [PCT , (21.34 ± 3.04) ng/L vs .(15.61 ± 2.32) ng/L] ,NT‐proBNP [ (298.37 ± 53.28) pg/ml vs .(104.28 ± 13.17) pg/ml] and sI‐CAM‐1 [ (391.83 ± 75.04) ng/ml vs .(162.18 ± 30.26) ng/ml] in Hcy‐lowering group , P<0.05 all .Conclusion:Hcy‐lowering therapy is help to reduce serum Hcy level ,relieve systemic inflammatory response and protect myocar‐dial function in CHD patients after PCI .